The Science
Precision Medical Management
Numerous clinical studies have documented that PGx testing leads to improved clinical outcomes and significant costs savings in the right patient populations.
Annual medical costs for certain patient populations may run as much as $5,188 more per year in the absence of PGx testing to determine optimal treatments compared to situations when pharmacogenetic data was applied1
PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control2
PGx testing represents a promising strategy to reduce costs and utilization among patients with mood and anxiety disorders. six-month cost of care was $1,948 lower per individual in the tested group versus the control group3
PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control4
Download our Research and Results Summary
Our team has complied a summary of some of the notable research and outcomes from the world of precision medical management and genomics
Read More
For Payors
A turnkey pharmacogenomics risk management and medication optimization platform for employers, health plans, third-party administrators and other payors
The Study
Pharmacogenomic testing and case management for members with complex chronic disease.
Improving Clinical Outcomes
Read more about the people behind it all.
1. https://www.futuremedicine.com/doi/pdf/10.2217/pme-2018-0074
2 .J. Med Econ. 2016;19(3): 213-28 Epub Nov 11, 2015
4. Plos ONE 12(2): e0170905. htts://doi.org10.1371/journal.pone.170905
Copyright 2019 © Rx-Precision, Inc. All rights reserved.
Rx-Precision, Inc.
2945 Townsgate Rd.
Suite #200
Westlake Village, CA 91361
The Science
Precision Medical Management
Numerous clinical studies have documented that PGx testing leads to improved clinical outcomes and significant costs savings in the right patient populations.
Annual medical costs for certain patient populations may run as much as $5,188 more per year in the absence of PGx testing to determine optimal treatments compared to situations when pharmacogenetic data was applied1
PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control2
PGx testing represents a promising strategy to reduce costs and utilization among patients with mood and anxiety disorders. six-month cost of care was $1,948 lower per individual in the tested group versus the control group3
PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control4
Download our Research and Results Summary
Our team has complied a summary of some of the notable research and outcomes from the world of precision medical management and genomics
Read More
For Payors
A turnkey pharmacogenomics risk management and medication optimization platform for employers, health plans, third-party administrators and other payors
The Study
Pharmacogenomic testing and case management for members with complex chronic disease.
Improving Clinical Outcomes
Read more about the people behind it all.
1. https://www.futuremedicine.com/doi/pdf/10.2217/pme-2018-0074
2 .J. Med Econ. 2016;19(3): 213-28 Epub Nov 11, 2015
4. Plos ONE 12(2): e0170905. htts://doi.org10.1371/journal.pone.170905
Copyright 2019 © Rx-Precision, Inc. All rights reserved.
Rx-Precision, Inc.
2945 Townsgate Rd.
Suite #200
Westlake Village, CA 91361
Oren is an innovator and technologist with deep experience in healthcare, big data and analytics. He has over 20 years’ experience as an entrepreneur and startup leader. Oren has had proven success in leading the creation of new products, businesses and venture-backed portfolios both as an entrepreneur and in partnership with Fortune 500 / Global 1000 companies. Oren is passionate about building transformative solutions and highly effective teams. He has expertise in artificial intelligence, deep learning, and data science across financial services, healthcare, and industrial sectors. Oren’s recent experience includes being Co-Founder and President of Pivotus Ventures, a new breed of enterprise software company focused in the banking industry that recently sold to Kony. Previously he was General Partner and Chief Strategy and Technology officer at FDC, a venture fund and startup foundry based in Orange County, CA. At FDC Oren ran incubation and oversaw technology and strategy across a portfolio of over 20 new ventures created at FDC.
Dr. Martin Kohn is an expert in health data analytics, health policy and healthcare management. He is an experienced physician, clinical informaticist, and health policy analyst. He was most recently Chief Medical Scientist at Sentrian, which creates predictive analytic systems integrating home monitoring with longitudinal health data for patients with complex chronic diseases. Sentrian identifies patients who are likely to need hospitalization days before they become seriously ill to provide time to intervene and avoid hospitalization. Previously, he was the Chief Medical Scientist for Care Delivery Systems in IBM Research developing analytic tools for healthcare, including the use of the Watson supercomputer.
Roni has more 20 years of industry healthcare technology experience in roles as CTO, CIO and CISO at Health Systems, Pharmaceutical, Biotechnology, Payer, Academic, City/State Government and Medical device companies.
As Chief Financial Officer, Shital is responsible for all of the company’s financial functions including accounting, audit, treasury, corporate finance and investor relations. Shital also leads human resource and legal activities. Her career spans more than 15 years of varied experience in financial management, business leadership and corporate strategy for software companies. Prior to joining Rx-Precision, Shital held previous CFO and Management positions at Pivotus Ventures, Maana and Microsoft. Shital earned a Bachelors of Speech Communication from California State University of Fullerton.
As COO, Joshua designed, built and manages our case management operations which includes member enrollment, testing and all activities between the lab, member, genetic counselors and treating physicians.
Jake has owned and operated family medicine, integrated health, and behavioral health clinics where he saw first hand how clinical solutions and advancements based on precision medicine can change the way we treat disease.
Dean is a healthcare industry veteran and digital health pioneer with more than twenty years of hands-on digital health experience as a startup Founder, CEO, Chief Commercial Officer and VP of Sales. Dean also has experience as a Partner and Advisor for venture capital firms and startup incubators, accelerators and growth foundries.
Dr. Bleyl is board-certified in medical genetics with a doctorate degree in human genetics and background experience spanning clinical care, academic research and oversight of clinical services across an integrated health system. Prior to this role, he directed the Clinical Genetics Institute (CGI) for Intermountain Healthcare, where he oversaw provision of genetic services, implementation of genetic testing stewardship and development of a system-wide infrastructure for storage and use of genomic data. Dr. Bleyl maintains an academic affiliation with the University of Utah, where his clinical practice focuses on cardiovascular genetics.
Guru is driven to develop and apply deep technology innovations to solve the big challenges, especially in health and education. He is known for his work on Microbiome Analytics, IBM Watson AI, Smarter Cities, Services Innovation, Mobile Computing, and Distributed Systems.
Tyler Koep, PhD is a Medical Affairs Specialist at OneOme specializing in clinical research and data analytics. Tyler received his PhD from Mayo Graduate School with a focus in Biomedical Sciences in 2014 and completed a post-doctoral fellowship at the University of Minnesota in 2017. Dr. Koep has numerous publications within the field of epidemiology and public health and provides expertise in designing and executing clinical research studies. Further, Dr. Koep offers subject matter expertise across the field of pharmacogenomics, including scientific foundations of drug metabolism, cost-effectiveness of pharmacogenomic testing, and chronic disease applications
